نتایج جستجو برای: chemoimmunotherapy
تعداد نتایج: 698 فیلتر نتایج به سال:
BACKGROUND To investigate the impact of high dose chemoimmunotherapy in addition to surgery on the cumulative survival and disease-free survey of malignant melanoma patients. METHODS A total of 86 malignant melanoma patients [35 females (40.7%), 51 males (59.3%), mean age: 55.5] were treated according to their stages between Februrary 1997 and June 2007. After surgery, adjuvant immunotherapy ...
The monoclonal antibody targeting CD52, alemtuzumab, has a more potent antileukemic activity compared with the antibody targeting CD20, rituximab. CLL cells express more CD52 than CD20.3 Finally, the combination of fludarabine with alemtuzumab (FA) was shown to be effective and safe.4,5 Hence, it seemed a logical step to combine alemtuzumab with FC chemotherapy, the most efficient backbone of c...
BACKGROUND/AIM Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients. MATERIALS AND METHODS Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and...
To the Editor: I would like to congratulate Bosch and colleagues on a well-conducted clinical investigation confirming the activity of the FCM (fludarabine, cyclophosphamide, and mitoxantrone) program in previously untreated chronic lymphocytic leukemia (1). Bosch and colleagues reported that FCM provides an overall response rate of 90% with a complete response of 64%. In addition, using a high...
The combination of a single low dose of cyclophosphamide (Cy) with the adenovirus-mediated gene transfer of interleukin-12 (AdIL-12) might represent a successful therapy for experimental gastrointestinal tumors. This approach has been proven to revert immunosuppressive mechanisms elicited by cancer cells and to synergistically promote antitumor immunity. In addition, this therapeutic regimen ha...
Follicular lymphoma (FL) is one of the most common types of non-Hodgkin's lymphoma. It is usually diagnosed at an advanced stage, for which many treatment options exist, however, no curative standard therapy has been identified. The outcome is highly variable with a median survival of approximately 10 years. The life expectancy of patients with FL has been extended with the use of rituximab, a ...
Primary cardiac lymphoma (PCL) is a rare neoplasm that involves the heart, pericardium, or both. Patients with PCL have median survival of approximately 7 months. We report a 63-year-old woman with PCL treated with chemoimmunotherapy but relapsed 7 years later. She received automated implantable cardioverter-defibrillator (AICD) prophylactically shortly after the diagnosis. She presented with a...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید